CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Genzyme Corporation v. Novartis Gene Therapies, Inc.

1:23-cv-00554

Overview

Case Number 1:23-cv-00554
Filing Date 2023-05-19
Status Terminated
Termination Date 2024-02-14
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:1 Patent Infringement
Jury Demand Plaintiff

Parties

Defendant

Novartis Gene Therapies, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Genzyme Corporation NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials 2 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (2 found):
PTAB: 2
USPTO PTAB Trial 2023-06-30
IPR2023-01045

Novartis Gene Therapies, Inc. et al. v. Aventis, Inc. et al.

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2023-06-30
IPR2023-01044

Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation et al.

Asserted Patent
Status: Terminated-Settled
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US10429288
Analytical ultracentrifugation for characterization of recombinant viral particles
Filed: 2016-01-19
Issued: 2019-10-01
Active (9.2 yrs remaining)
Expires: 2036-01-19

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).

Docket Entries

(20 total)
Pleading / Complaint

COMPLAINT filed with Jury Demand against Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation ( Filing fee $ 402, receipt number ADEDC-4140805.) - filed by Genzyme Corporation, Aventis Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(twk) (Entered: 05/19/2023)

Entry #1 • 2023-05-19
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 05/19/2023)

Entry #2 • 2023-05-19
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,429,288. (twk) (Entered: 05/19/2023)

Entry #3 • 2023-05-19
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Sanofi for Aventis Inc., Genzyme Corporation filed by Aventis Inc., Genzyme Corporation. (twk) (Entered: 05/19/2023)

Entry #4 • 2023-05-19
1

Summons Issued as to Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation on 5/19/2023. (Attachments: # 1 Summons Issued)(twk) (Entered: 05/19/2023)

Entry #5 • 2023-05-19
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc